260 results on '"Pomerantz RJ"'
Search Results
2. SV40-derived vectors provide effective transgene expression and inhibition of HIV-1 using constitutive, conditional,and pol III promoters
- Author
-
Jayan, GC, Cordelier, P, Patel, C, BouHamdan, M, Johnson, R Paul, Lisziewicz, J, Pomerantz, RJ, and Strayer, DS
- Published
- 2001
- Full Text
- View/download PDF
3. Inhibition of HIV-1 infection by down-regulation of the CXCR4 co-receptor using an intracellular single chain variable fragment against CXCR4
- Author
-
BouHamdan, M, Strayer, DS, Wei, D, Mukhtar, M, Duan, L-X, Hoxie, J, and Pomerantz, RJ
- Published
- 2001
- Full Text
- View/download PDF
4. Intracellular inhibition of HIV-1 replication using a dual protein- and RNA-based strategy
- Author
-
Duan, L, Zhu, M, Ozaki, I, Zhang, H, Wei, DL, and Pomerantz, RJ
- Published
- 1997
- Full Text
- View/download PDF
5. Erratum: Intracellular inhibition of HIV-1 replication using a dual protein- and RNA-based strategy
- Author
-
Duan, L-X, Zhu, M, Ozaki, I, Wei, DL, and Pomerantz, RJ
- Published
- 1998
- Full Text
- View/download PDF
6. Genetic therapies for HIV infections
- Author
-
Pomerantz Rj and Trono D
- Subjects
medicine.medical_treatment ,Genetic enhancement ,Immunology ,HIV Infections ,Virus Replication ,Virus ,Acquired immunodeficiency syndrome (AIDS) ,Immunopathology ,medicine ,Humans ,Immunology and Allergy ,Sida ,Gene ,biology ,business.industry ,Genetic Therapy ,Immunotherapy ,medicine.disease ,biology.organism_classification ,Virology ,Infectious Diseases ,HIV-2 ,HIV-1 ,Viral disease ,business ,Forecasting - Published
- 1995
7. HIV-1 mediated neuronal apoptosis and molecular mechanisms of HIV-1-induced encephalopathy
- Author
-
Xu, Y, Sullivan, J, Acheampong, E, Nunnari, G, and Pomerantz, Rj
- Published
- 2004
8. Kynurenine pathway metabolism in human blood-brain-barrier cells: implications for immune tolerance & neurotoxicity
- Author
-
Owe-Young, R, Webster, NL, Mukhtar, M, Pomerantz, RJ, Smythe, G, Walker, D, Armati, PJ, Crowe, SM, Brew, BJ, Owe-Young, R, Webster, NL, Mukhtar, M, Pomerantz, RJ, Smythe, G, Walker, D, Armati, PJ, Crowe, SM, and Brew, BJ
- Abstract
The catabolic pathway of l-tryptophan (l-trp), known as the kynurenine pathway (KP), has been implicated in the pathogenesis of a wide range of brain diseases through its ability to lead to immune tolerance and neurotoxicity. As endothelial cells (ECs) and pericytes of the blood-brain-barrier (BBB) are among the first brain-associated cells that a blood-borne pathogen would encounter, we sought to determine their expression of the KP. Using RT-PCR and HPLC/GC-MS, we show that BBB ECs and pericytes constitutively express components of the KP. BBB ECs constitutively synthesized kynurenic acid, and after immune activation, kynurenine (KYN), which is secreted basolaterally. BBB pericytes produced small amounts of picolinic acid and after immune activation, KYN. These results have significant implications for the pathogenesis of inflammatory brain diseases in general, particularly human immunodeficiency virus (HIV)-related brain disease. Kynurenine pathway activation at the BBB results in local immune tolerance and neurotoxicity: the basolateral secretion of excess KYN can be further metabolized by perivascular macrophages and microglia with synthesis of quinolinic acid. The results point to a mechanism whereby a systemic inflammatory signal can be transduced across an intact BBB to cause local neurotoxicity.
- Published
- 2008
9. OVERVIEW
- Author
-
François Clavel and Pomerantz Rj
- Subjects
Secondary problem ,Viral pathogenesis ,Immunology ,Human immunodeficiency virus (HIV) ,Biology ,medicine.disease_cause ,medicine.disease ,Antiretroviral therapy ,Virology ,Chemokine receptor ,Infectious Diseases ,Viral genetics ,Acquired immunodeficiency syndrome (AIDS) ,medicine ,Immunology and Allergy ,HIV drug resistance - Abstract
The virology section of this 2001 ‘A Year in Review issue covers a large spectrum of HIV research topics. Even if these fields may appear similar to those covered in previous review issues the amount of knowledge that has accumulated recently within each of these domains is truly impressive. Research on HIV entry into target cells still benefits from the momentum provided by the 1995 discovery of the role of the chemokine receptors. Research on HIV assembly has become a more comprehensive field as detailed knowledge on protein structure and protein interactions has emerged. Research on HIV accessory genes has widened and gained in complexity as novel cellular partners have been identified bringing further insight into the complex network of interactions that underlies the regulation of HIV replication in its host cell. In the shadow of the major therapeutic advances of highly active antiretroviral therapy HIV drug resistance has emerged as a field of increasing interest and complexity altogether relevant to clinical management of HIV infection protein structure/function relationships viral genetics and viral pathogenesis. Finally HIV-2 long considered a remote and secondary problem has been the subject of studies that are likely to have a significant impact on multiple domains of HIV research. (excerpt)
- Published
- 2001
10. Highly attenuated rabies virus-based vaccine vectors expressing simian-human immunodeficiency virus89.6p Env and simian immunodeficiency virusmac239 Gag are safe in rhesus macaques and protect from an AIDS-like disease.
- Author
-
McKenna PM, Koser ML, Carlson KR, Montefiori DC, Letvin NL, Papaneri AB, Pomerantz RJ, Dietzschold B, Silvera P, McGettigan JP, and Schnell MJ
- Abstract
We analyzed the safety and immunogenicity of attenuated rabies virus vectors expressing simian-human immunodeficiency virus (SHIV)-1(89.6P) Env or simian immunodeficiency virus (SIV)(mac239) Gag in rhesus macaques. Four test macaques were immunized with both vaccine constructs, and 2 control macaques received an empty rabies vector. Seroconversion against rabies virus glycoprotein (G) and SHIV(89.6P) Env was detected after the initial immunization, but no cellular responses against SHIV antigens were observed. HIV/SIV-specific immune responses were not enhanced by boosts with the same vectors. Therefore, we constructed vectors expressing SHIV(89.6P) Env and SIV(mac239) Gag in which the rabies G was replaced with the G protein of vesicular stomatitis virus (VSV). Two years after initial immunization, a boost with the rabies-VSV G vectors resulted in SIV/HIV-specific immune responses. Upon challenge with SHIV(89.6P) test macaques controlled the infection, whereas control macaques had high levels of viremia and a profound loss of CD4(+) T cells, with 1 control macaque dying of an AIDS-like disease. Copyright © 2006 Infectious Diseases Society of America [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
11. Protecting from R5-tropic HIV: individual and combined effectiveness of a hammerhead ribozyme and a single-chain Fv antibody that targets CCR5.
- Author
-
Cordelier, P, Kulkowsky, JW, Ko, C, Matskevitch, AA, McKee, HJ, Rossi, JJ, Bouhamdan, M, Pomerantz, RJ, Kari, G, and Strayer, DS
- Subjects
HIV ,CATALYTIC RNA ,CHEMOKINES ,GENE therapy ,HIV infections ,RECOMBINANT viruses - Abstract
The CCR5 chemokine receptor is important for most clinical strains of HIV to establish infection. Individuals with naturally occurring polymorphisms in the CCR5 gene who have reduced or absent CCR5 are apparently otherwise healthy, but are resistant to HIV infection. With the goal of reducing CCR5 and protecting CCR5
+ cells from R5-tropic HIV, we used Tag-deleted SV40-derived vectors to deliver several anti-CCR5 transgenes: 2C7, a single-chain Fv (SFv) antibody; VCKA1, a hammerhead ribozyme; and two natural CCR5 ligands, MIP-1α and MIP-1β, modified to direct these chemokines, and hence their receptor to the endoplasmic reticulum. These transgenes were delivered using recombinant, Tag-deleted SV40-derived vectors to human CCR5+ cell lines and primary cells: monocyte-derived macrophages and brain microglia. All transgenes except MIP-1α decreased CCR5, as assayed by immunostaining, Northern blotting, and cytofluorimetry (FACS). Individually, all transgenes except MIP-1α protected from low challenge doses of HIV. At higher dose HIV challenges, protection provided by all transgenes diminished, the SFv and the ribozyme being most potent. Vectors carrying these two transgenes were used sequentially to deliver combination anti-CCR5 genetic therapy. This approach gave approximately additive reduction in CCR5, as measured by FACS and protected from higher dose HIV challenges. Reducing cell membrane CCR5 using anti-CCR5 transgenes, alone or in combinations, may therefore provide a degree of protection from R5-tropic strains of HIV. [ABSTRACT FROM AUTHOR]- Published
- 2004
- Full Text
- View/download PDF
12. How HIV resists eradication.
- Author
-
Pomerantz RJ
- Published
- 1998
13. Human herpesvirus type 8 DNA sequences in cell-free plasma and mononuclear cells of Kaposi's sarcoma patients.
- Author
-
Harrington WJ Jr, Bagasra O, Sosa CE, Bobroski LE, Baum M, Wen XL, Cabral L, Byrne GE, Pomerantz RJ, Wood C, Harrington, W J Jr, Bagasra, O, Sosa, C E, Bobroski, L E, Baum, M, Wen, X L, Cabral, L, Byrne, G E, Pomerantz, R J, and Wood, C
- Abstract
Human herpesvirus (HHV) type 8 has been detected in both classical and AIDS-related Kaposi's sarcoma, body-cavity lymphomas, and other types of tumors. HHV-8 has also been detected in DNA from peripheral blood mononuclear cells (PBMC) of some Kaposi's sarcoma patients and more readily in B cell fractions derived from panned cell subpopulations. Two patients were followed using several methods; in situ hybridization, solution-based polymerase chain reaction (PCR), and in situ PCR. HHV-8 was intermittently detected in plasma, and detection correlated with detection in PBMC. In situ PCR demonstrated HHV-8 sequences in both peripheral blood B lymphocytes and, to a lesser extent, T lymphocytes. HHV-8 may undergo periods of viremia while at other times it is undetectable and infects circulating B cells and some T cells. [ABSTRACT FROM AUTHOR]
- Published
- 1996
- Full Text
- View/download PDF
14. HIV and GB virus C -- can two viruses be better than one?
- Author
-
Pomerantz RJ and Nunnari G
- Published
- 2004
15. The expert speaks. Immune reconstitution syndrome in AIDS.
- Author
-
Glaser V and Pomerantz RJ
- Published
- 2003
16. Initiating antiretroviral therapy during HIV infection: confusion and clarity.
- Author
-
Pomerantz RJ and Pomerantz, R J
- Published
- 2001
- Full Text
- View/download PDF
17. Human immunodeficiency virus type 1 in the semen of men receiving highly active antiretroviral therapy.
- Author
-
Zhang H, Dornadula G, Beumont M, Livornese L Jr., Van Uitert B, Henning K, and Pomerantz RJ
- Published
- 1998
18. SER-109, an Investigational Microbiome Drug to Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 Trial.
- Author
-
McGovern BH, Ford CB, Henn MR, Pardi DS, Khanna S, Hohmann EL, O'Brien EJ, Desjardins CA, Bernardo P, Wortman JR, Lombardo MJ, Litcofsky KD, Winkler JA, McChalicher CWJ, Li SS, Tomlinson AD, Nandakumar M, Cook DN, Pomerantz RJ, Auninš JG, and Trucksis M
- Subjects
- Aged, Clostridioides, Drugs, Investigational, Female, Humans, Male, Recurrence, Clostridioides difficile, Clostridium Infections drug therapy, Clostridium Infections prevention & control, Microbiota
- Abstract
Background: Recurrent Clostridioides difficile infection (rCDI) is associated with loss of microbial diversity and microbe-derived secondary bile acids, which inhibit C. difficile germination and growth. SER-109, an investigational microbiome drug of donor-derived, purified spores, reduced recurrence in a dose-ranging, phase (P) 1 study in subjects with multiple rCDIs., Methods: In a P2 double-blind trial, subjects with clinical resolution on standard-of-care antibiotics were stratified by age (< or ≥65 years) and randomized 2:1 to single-dose SER-109 or placebo. Subjects were diagnosed at study entry by PCR or toxin testing. Safety, C. difficile-positive diarrhea through week 8, SER-109 engraftment, and bile acid changes were assessed., Results: 89 subjects enrolled (67% female; 80.9% diagnosed by PCR). rCDI rates were lower in the SER-109 arm than placebo (44.1% vs 53.3%) but did not meet statistical significance. In a preplanned analysis, rates were reduced among subjects ≥65 years (45.2% vs 80%, respectively; RR, 1.77; 95% CI, 1.11-2.81), while the <65 group showed no benefit. Early engraftment of SER-109 was associated with nonrecurrence (P < .05) and increased secondary bile acid concentrations (P < .0001). Whole-metagenomic sequencing from this study and the P1 study revealed previously unappreciated dose-dependent engraftment kinetics and confirmed an association between early engraftment and nonrecurrence. Engraftment kinetics suggest that P2 dosing was suboptimal. Adverse events were generally mild to moderate in severity., Conclusions: Early SER-109 engraftment was associated with reduced CDI recurrence and favorable safety was observed. A higher dose of SER-109 and requirements for toxin testing were implemented in the current P3 trial., Clinical Trials Registration: NCT02437487, https://clinicaltrials.gov/ct2/show/NCT02437487?term=SER-109&draw= 2&rank=4., (© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America.)
- Published
- 2021
- Full Text
- View/download PDF
19. A Phase 1b Safety Study of SER-287, a Spore-Based Microbiome Therapeutic, for Active Mild to Moderate Ulcerative Colitis.
- Author
-
Henn MR, O'Brien EJ, Diao L, Feagan BG, Sandborn WJ, Huttenhower C, Wortman JR, McGovern BH, Wang-Weigand S, Lichter DI, Chafee M, Ford CB, Bernardo P, Zhao P, Simmons S, Tomlinson AD, Cook DN, Pomerantz RJ, Misra BK, Auninš JG, and Trucksis M
- Subjects
- Adult, Double-Blind Method, Female, Humans, Male, Middle Aged, Spores, Colitis, Ulcerative therapy, Firmicutes, Gastrointestinal Microbiome
- Abstract
Background & Aims: Firmicutes bacteria produce metabolites that maintain the intestinal barrier and mucosal immunity. Firmicutes are reduced in the intestinal microbiota of patients with ulcerative colitis (UC). In a phase 1b trial of patients with UC, we evaluated the safety and efficacy of SER-287, an oral formulation of Firmicutes spores, and the effects of vancomycin preconditioning on expansion (engraftment) of SER-287 species in the colon., Methods: We conducted a double-blind trial of SER-287 in 58 adults with active mild-to-moderate UC (modified Mayo scores 4-10, endoscopic subscores ≥1). Participants received 6 days of preconditioning with oral vancomycin (125 mg, 4 times daily) or placebo followed by 8 weeks of oral SER-287 or placebo. Patients were randomly assigned (2:3:3:3) to groups that received placebo followed by either placebo or SER-287 once weekly, or vancomycin followed by SER-287 once weekly, or SER-287 once daily. Clinical end points included safety and clinical remission (modified Mayo score ≤2; endoscopic subscores 0 or 1). Microbiome end points included SER-287 engraftment (dose species detected in stool after but not before SER-287 administration). Engraftment of SER-287 and changes in microbiome composition and associated metabolites were measured by analyses of stool specimens collected at baseline, after preconditioning, and during and 4 weeks after administration of SER-287 or placebo., Results: Proportions of patients with adverse events did not differ significantly among groups. A higher proportion of patients in the vancomycin/SER-287 daily group (40%) achieved clinical remission at week 8 than patients in the placebo/placebo group (0%), placebo/SER-287 weekly group (13.3%), or vancomycin/SER-287 weekly group (17.7%) (P = .024 for vancomycin/SER-287 daily vs placebo/placebo). By day 7, higher numbers of SER-287 dose species were detected in stool samples from all SER-287 groups compared with the placebo group (P < .05), but this difference was not maintained beyond day 7 in the placebo/SER-287 weekly group. In the vancomycin groups, a greater number of dose species were detected in stool collected on day 10 and all subsequent time points through 4 weeks post dosing compared with the placebo group (P < .05). A higher number of SER-287 dose species were detected in stool samples on days 7 and 10 from subjects who received daily vs weekly SER-287 doses (P < .05). Changes in fecal microbiome composition and metabolites were associated with both vancomycin/SER-287 groups., Conclusions: In this small phase 1b trial of limited duration, the safety and tolerability of SER-287 were similar to placebo. SER-287 after vancomycin was significantly more effective than placebo for induction of remission in patients with active mild to moderate UC. Engraftment of dose species was facilitated by vancomycin preconditioning and daily dosing of SER-287. ClinicalTrials.gov ID NCT02618187., (Copyright © 2021. Published by Elsevier Inc.)
- Published
- 2021
- Full Text
- View/download PDF
20. Reply to Lagier et al.
- Author
-
Khanna S, Button JE, Lombardo MJ, Vulic M, Henn MR, Cook DN, Pomerantz RJ, and Hohmann EL
- Published
- 2017
- Full Text
- View/download PDF
21. A Novel Microbiome Therapeutic Increases Gut Microbial Diversity and Prevents Recurrent Clostridium difficile Infection.
- Author
-
Khanna S, Pardi DS, Kelly CR, Kraft CS, Dhere T, Henn MR, Lombardo MJ, Vulic M, Ohsumi T, Winkler J, Pindar C, McGovern BH, Pomerantz RJ, Aunins JG, Cook DN, and Hohmann EL
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Biological Therapy adverse effects, Diarrhea prevention & control, Female, Humans, Male, Middle Aged, Young Adult, Biological Therapy methods, Clostridioides difficile growth & development, Clostridium Infections prevention & control, Gastrointestinal Microbiome, Gastrointestinal Tract microbiology, Secondary Prevention methods
- Abstract
Background: Patients with recurrent Clostridium difficile infection (CDI) have a ≥60% risk of relapse, as conventional therapies do not address the underlying gastrointestinal dysbiosis. This exploratory study evaluated the safety and efficacy of bacterial spores for preventing recurrent CDI., Methods: Stool specimens from healthy donors were treated with ethanol to eliminate pathogens. The resulting spores were fractionated and encapsulated for oral delivery as SER-109. Following their response to standard-of-care antibiotics, patients in cohort 1 were treated with SER-109 on 2 consecutive days (geometric mean dose, 1.7 × 10(9) spores), and those in cohort 2 were treated on 1 day (geometric mean dose, 1.1 × 10(8) spores). The primary efficacy end point was absence of C. difficile-positive diarrhea during an 8-week follow-up period. Microbiome alterations were assessed., Results: Thirty patients (median age, 66.5 years; 67% female) were enrolled, and 26 (86.7%) met the primary efficacy end point. Three patients with early, self-limiting C. difficile-positive diarrhea did not require antibiotics and tested negative for C. difficile at 8 weeks; thus, 96.7% (29 of 30) achieved clinical resolution. In parallel, gut microbiota rapidly diversified, with durable engraftment of spores and no outgrowth of non-spore-forming bacteria found after SER-109 treatment. Adverse events included mild diarrhea, abdominal pain, and nausea., Conclusions: SER-109 successfully prevented CDI and had a favorable safety profile, supporting a novel microbiome-based intervention as a potential therapy for recurrent CDI., (© The Author 2016. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail journals.permissions@oup.com.)
- Published
- 2016
- Full Text
- View/download PDF
22. Generation of retroviral particles for the spleen necrosis virus (SNV)-based vector system and their use in transduction of various cell types.
- Author
-
Parveen Z, Mukhtar M, and Pomerantz RJ
- Subjects
- Cell Line, Humans, Mitosis, Neurons cytology, Neurons metabolism, Subcellular Fractions metabolism, Transfection, Genetic Vectors genetics, Trager duck spleen necrosis virus genetics, Transduction, Genetic methods, Virion genetics
- Abstract
Genetically engineered retroviruses are widely used for gene delivery into human cells. A number of investigators have studied spleen necrosis virus (SNV) as a vehicle for gene delivery. Vectors developed from SNV and its closely associated avian reticuloendotheliosis virus strain A (REV-A) can be used for gene transfer into a variety of cells, including primary hematopoietic cells and human brain and post-mitotic neuronal cells that are difficult to transduce with other vector systems. SNV-based vector systems have the advantage of being quite safe, because wild-type SNV is unable to infect human cells and has less preference for integration into transcriptionally active sites or genes. However, the generation of retroviral vectors requires cotransfection of more than one plasmid into a packaging cell line, which is a tedious process. The development of stable packaging cell lines expressing envelope (Env) proteins and the structural proteins Gag-Pol will enhance mass production of retroviral vectors for future gene therapy experiments both in vitro and in vivo. This protocol describes the generation of retroviral particles for the SNV-based vector system. These particles can then be used for transduction of various cell types; as an example, a technique for transduction of post-mitotic neurons is also presented.
- Published
- 2010
- Full Text
- View/download PDF
23. Combined effects of hyperglycemic conditions and HIV-1 Nef: a potential model for induced HIV neuropathogenesis.
- Author
-
Acheampong EA, Roschel C, Mukhtar M, Srinivasan A, Rafi M, Pomerantz RJ, and Parveen Z
- Subjects
- Animals, Apoptosis, Astrocytes pathology, HIV Infections pathology, Inflammation Mediators metabolism, Mice, Mice, Inbred C57BL, Mice, Inbred NOD, Diabetes Complications, HIV Infections complications, HIV-1 pathogenicity, Virulence Factors physiology, nef Gene Products, Human Immunodeficiency Virus physiology
- Abstract
Hyperglycemic conditions associated with diabetes mellitus (DM) or with the use of antiretroviral therapy may increase the risk of central nervous system (CNS) disorders in HIV-1 infected patients. In support of this hypothesis, we investigated the combined effects of hyperglycemic conditions and HIV-1 accessory protein Nef on the CNS using both in vitro and in vivo models. Astrocytes, the most abundant glial cell type required for normal synaptic transmission and other functions were selected for our in vitro study. The results show that in vitro hyperglycemic conditions enhance the expression of proinflammatory cytokines including caspase-3, complement factor 3 (C3), and the production of total nitrate and 8-iso-PGF2 alpha as reactive oxygen species (ROS) in human astrocytes leading to cell death in a dose-dependent manner. Delivery of purified recombinant HIV-1 Nef protein, or Nef expressed via HIV-1-based vectors in astrocytes showed similar results. The expression of Nef protein delivered via HIV-1 vectors in combination with hyperglycemia further augmented the production of ROS, C3, activation of caspase-3, modulation of filamentous protein (F-protein), depolarization of the mitochondria, and loss of astrocytes. To further verify the effects of hyperglycemia and HIV-1 Nef protein on CNS individually or in combination, in vivo studies were performed in streptozotocin (STZ) induced diabetic mice, by injecting HIV-1 Nef expressing viral particles into the sub-cortical region of the brain. Our in vivo results were similar to in vitro findings indicating an enhanced production of caspases-3, ROS (lipid oxidation and total nitrate), and C3 in the brain tissues of these animals. Interestingly, the delivery of HIV-1 Nef protein alone caused similar damage to CNS as augmented by hyperglycemia conditions. Taken together, the data suggests that HIV-1 infected individuals with hyperglycemia could potentially be at a higher risk of developing CNS related complications.
- Published
- 2009
- Full Text
- View/download PDF
24. The challenge of finding a cure for HIV infection.
- Author
-
Richman DD, Margolis DM, Delaney M, Greene WC, Hazuda D, and Pomerantz RJ
- Subjects
- AIDS Vaccines, Animals, Anti-HIV Agents economics, Antiretroviral Therapy, Highly Active adverse effects, Antiretroviral Therapy, Highly Active economics, CD4-Positive T-Lymphocytes virology, Clinical Trials as Topic, Drug Discovery, HIV physiology, HIV Infections virology, Humans, Viremia drug therapy, Virus Replication drug effects, Anti-HIV Agents therapeutic use, HIV drug effects, HIV Infections drug therapy, Virus Latency drug effects
- Abstract
Although combination therapy for HIV infection represents a triumph for modern medicine, chronic suppressive therapy is required to contain persistent infection in reservoirs such as latently infected CD4+ lymphocytes and cells of the macrophage-monocyte lineage. Despite its success, chronic suppressive therapy is limited by its cost, the requirement of lifelong adherence, and the unknown effects of long-term treatment. This review discusses our current understanding of suppressive antiretroviral therapy, the latent viral reservoir, and the needs for and challenges of attacking this reservoir to achieve a cure.
- Published
- 2009
- Full Text
- View/download PDF
25. Kynurenine pathway metabolism in human blood-brain-barrier cells: implications for immune tolerance and neurotoxicity.
- Author
-
Owe-Young R, Webster NL, Mukhtar M, Pomerantz RJ, Smythe G, Walker D, Armati PJ, Crowe SM, and Brew BJ
- Subjects
- Blood-Brain Barrier immunology, Blood-Brain Barrier pathology, Cells, Cultured, Endothelial Cells immunology, Endothelial Cells metabolism, Endothelial Cells pathology, Humans, Kynurenine genetics, Kynurenine metabolism, Neurotoxicity Syndromes genetics, Neurotoxicity Syndromes pathology, Pericytes immunology, Pericytes metabolism, Pericytes pathology, Blood-Brain Barrier metabolism, Immune Tolerance, Kynurenine physiology, Neurotoxicity Syndromes metabolism, Signal Transduction immunology
- Abstract
The catabolic pathway of l-tryptophan (l-trp), known as the kynurenine pathway (KP), has been implicated in the pathogenesis of a wide range of brain diseases through its ability to lead to immune tolerance and neurotoxicity. As endothelial cells (ECs) and pericytes of the blood-brain-barrier (BBB) are among the first brain-associated cells that a blood-borne pathogen would encounter, we sought to determine their expression of the KP. Using RT-PCR and HPLC/GC-MS, we show that BBB ECs and pericytes constitutively express components of the KP. BBB ECs constitutively synthesized kynurenic acid, and after immune activation, kynurenine (KYN), which is secreted basolaterally. BBB pericytes produced small amounts of picolinic acid and after immune activation, KYN. These results have significant implications for the pathogenesis of inflammatory brain diseases in general, particularly human immunodeficiency virus (HIV)-related brain disease. Kynurenine pathway activation at the BBB results in local immune tolerance and neurotoxicity: the basolateral secretion of excess KYN can be further metabolized by perivascular macrophages and microglia with synthesis of quinolinic acid. The results point to a mechanism whereby a systemic inflammatory signal can be transduced across an intact BBB to cause local neurotoxicity.
- Published
- 2008
- Full Text
- View/download PDF
26. Antiviral potentials of medicinal plants.
- Author
-
Mukhtar M, Arshad M, Ahmad M, Pomerantz RJ, Wigdahl B, and Parveen Z
- Subjects
- Antiviral Agents isolation & purification, Humans, Antiviral Agents pharmacology, Plant Extracts pharmacology, Plants, Medicinal chemistry, Viruses drug effects
- Abstract
Medicinal plants have been widely used to treat a variety of infectious and non-infectious ailments. According to one estimate, 25% of the commonly used medicines contain compounds isolated from plants. Several plants could offer a rich reserve for drug discovery of infectious diseases, particularly in an era when the latest separation techniques are available on one hand, and the human population is challenged by a number of emerging infectious diseases on the other hand. Among several other ailments, viral infections, particularly infections associated with human immunodeficiency virus type 1 (HIV-1) and 2 (HIV-2), and newly emerging infectious viruses have challenged mankind survival. Of importance, a variety of medicinal plants have shown promise to treat a number of viral infections, and some of them possess broad-spectrum antiviral activity. In the past, exploration into the antiviral activity of various promising medicinal plants was limited due to: (a) highly infectious nature of viruses and (b) lack of appropriate separation techniques for the identification of antiviral components from plants. Development of vector-based strategies, in which non-infectious molecular clone of a virus could be used for antiviral screening purposes, and advancement in separation technologies offers promise for medicinal plants usage in modern drug discovery. This article describes potential antiviral properties of medicinal plants against a diverse group of viruses, and suggests screening the potential of plants possessing broad-spectrum antiviral effects against emerging viral infections.
- Published
- 2008
- Full Text
- View/download PDF
27. Hide-and-seek: the challenge of viral persistence in HIV-1 infection.
- Author
-
Geeraert L, Kraus G, and Pomerantz RJ
- Subjects
- Humans, Treatment Failure, Virus Activation, Virus Latency, Antiretroviral Therapy, Highly Active, HIV Infections drug therapy, HIV-1 physiology
- Abstract
The success of highly active antiretroviral therapy (HAART) for HIV-1 infection has sparked interest in mechanisms by which the virus can persist despite effectively suppressive therapy. Latent HIV-1 reservoirs established early during infection not only prevent sterilizing immunity but also represent a major obstacle to virus eradication. When HIV-1 gains a foothold in the immunologic memory or in certain inaccessible compartments of the human body, it cannot be easily purged by HAART and is able to replenish systemic infection on treatment interruption. Because latently infected cells are indistinguishable from uninfected cells, deliberate activation of latent infection combined with intensified HAART seems to be the best strategy to combat latent infection. Initial hypothesis-driven clinical trials did not achieve their ultimate goal, although they provided valuable insight for the design of future eradication protocols. A more detailed understanding of the basic mechanisms underlying the establishment and long-term maintenance of HIV-1 reservoirs will be critical in developing new eradication approaches.
- Published
- 2008
- Full Text
- View/download PDF
28. Effects of highly active antiretroviral therapy on HIV-1-associated oral complications.
- Author
-
Parveen Z, Acheampong E, Pomerantz RJ, Jacobson JM, Wigdahl B, and Mukhtar M
- Subjects
- Adult, Antiretroviral Therapy, Highly Active, Child, HIV Infections complications, HIV Infections transmission, Humans, Anti-HIV Agents therapeutic use, HIV Infections drug therapy, HIV-1, Mouth Diseases etiology
- Abstract
The oral cavity of human immunodeficiency virus type I (HIV-1) infected individuals is subjected to a series of opportunistic infections which are usually considered as a prognostic marker for the severity of infection as well as an indicator of immunodeficiency. The highly active antiretroviral therapy (HAART) has significantly lessened the severity of HIV-associated oral infections although this therapeutic regimen is considered to be responsible for some of the oral lesions such as oral warts and salivary gland disorders. In addition, the beneficial effects of HAART on HIV associated oral lesions are stratified with age, with the adult population showing improvements whereas the oral lesions among children remain unchanged with this therapy. The presence of HIV-1 in the saliva, and infectivity of oral epithelial cells suggest that the oral cavity is a site of HIV pathogenesis and potential reservoir for the disease in the setting of virally suppressive HAART. Overall HIV associated oral lesions are usually due to fungal, bacterial, and viral infections as well as some of unknown etiology. This review describes the current status of HIV associated oral lesions by comparing historically available pre-HAART data. Future directions envisioned by the National Institutes of Health as well as novel avenues to be explored are also presented.
- Published
- 2007
- Full Text
- View/download PDF
29. Cholesterol-depleting statin drugs protect postmitotically differentiated human neurons against ethanol- and human immunodeficiency virus type 1-induced oxidative stress in vitro.
- Author
-
Acheampong E, Parveen Z, Mengistu A, Ngoubilly N, Wigdahl B, Lossinsky AS, Pomerantz RJ, and Mukhtar M
- Subjects
- Central Nervous System Depressants pharmacology, HIV-1 metabolism, Humans, Neurons metabolism, Cholesterol metabolism, Ethanol pharmacology, HIV-1 drug effects, Hydroxymethylglutaryl-CoA Reductase Inhibitors pharmacology, Neurons drug effects, Oxidative Stress drug effects
- Abstract
The majority of human immunodeficiency virus type 1 (HIV-1)-infected individuals are either alcoholics or prone to alcoholism. Upon ingestion, alcohol is easily distributed into the various compartments of the body, particularly the brain, by crossing through the blood-brain barrier. Both HIV-1 and alcohol induce oxidative stress, which is considered a precursor for cytotoxic responses. Several reports have suggested that statins exert antioxidant as well as anti-inflammatory pleiotropic effects, besides their inherent cholesterol-depleting potentials. In our studies, postmitotically differentiated neurons were cocultured with HIV-1-infected monocytes, T cells, or their cellular supernatants in the presence of physiological concentrations of alcohol for 72 h. Parallel cultures were pretreated with statins (atorvastatin and simvastatin) with the appropriate controls, i.e., postmitotically differentiated neurons cocultured with uninfected cells and similar cultures treated with alcohol. The oxidative stress responses in the presence/absence of alcohol in these cultures were determined by the production of the well-characterized oxidative stress markers, 8-isoprostane-F2-alpha, total nitrates as an indicator for various isoforms of nitric oxide synthase activity, and heat shock protein 70 (Hsp70). An in vitro culture of postmitotically differentiated neurons with HIV-1-infected monocytes or T cells as well as supernatants from these cells enhanced the release of 8-isoprostane-F2-alpha in the conditioned medium six- to sevenfold (monocytes) and four- to fivefold (T cells). It was also observed that coculturing of HIV-1-infected primary monocytes over a time period of 72 h significantly elevated the release of Hsp70 compared with that of uninfected controls. Cellular supernatants of HIV-1-infected monocytes or T cells slightly increased Hsp70 levels compared to neurons cultured with uninfected monocytes or T-cell supernatants (controls). Ethanol (EtOH) presence further elevated Hsp70 in both infected and uninfected cultures. The amount of total nitrates was significantly elevated in the coculture system when both infected cells and EtOH were present. Surprisingly, pretreatment of postmitotic neurons with clinically available inhibitors of HMG-coenzyme A reductase (statins) inhibited HIV-1-induced release of stress/toxicity-associated parameters, i.e., Hsp70, isoprostanes, and total nitrates from HIV-1-infected cells. The results of this study provide new insights into HIV-1 neuropathogenesis aimed at the development of future HIV-1 therapeutics to eradicate viral reservoirs from the brain.
- Published
- 2007
- Full Text
- View/download PDF
30. HIV-1 Vpr potently induces programmed cell death in the CNS in vivo.
- Author
-
Cheng X, Mukhtar M, Acheampong EA, Srinivasan A, Rafi M, Pomerantz RJ, and Parveen Z
- Subjects
- Animals, Animals, Newborn, Brain metabolism, Cells, Cultured, Genetic Vectors, Humans, Mice, Mice, Inbred C57BL, Oligodendroglia pathology, Trager duck spleen necrosis virus genetics, vpr Gene Products, Human Immunodeficiency Virus, Apoptosis, Brain pathology, Gene Products, vpr physiology, HIV-1 metabolism
- Abstract
The human immunodeficiency virus type I (HIV-1) accessory protein Vpr has been associated with the induction of programmed cell death (apoptosis) and cell-cycle arrest. Studies have shown the apoptotic effect of Vpr on primary and established cell lines and on diverse tissues including the central nervous system (CNS) in vitro. However, the relevance of the effect of Vpr observed in vitro to HIV-1 neuropathogenesis in vivo, remains unknown. Due to the narrow host range of HIV-1 infection, no animal model is currently available. This has prompted us to consider a small animal model to evaluate the effects of Vpr on CNS in vivo through surrogate viruses expressing HIV-1Vpr. A single round of replication competent viral vectors, expressing Vpr, were used to investigate the apoptosis-inducing capabilities of HIV-1Vpr in vivo. Viral particles pseudotyped with VSV-G or N2c envelopes were generated from spleen necrosis virus (SNV) and HIV-1-based vectors to transduce CNS cells. The in vitro studies have demonstrated that Vpr generated by SNV vectors had less apoptotic effects on CNS cells compared with Vpr expressed by HIV-1 vectors. The in vivo study has suggested that viral particles, expressing Vpr generated by HIV-1-based vectors, when delivered through the ventricle, caused loss of neurons and dendritic processes in the cortical region. The apoptotic effect was extended beyond the cortical region and affected the hippocampus neurons, the lining of the choroids plexus, and the cerebellum. However, the effect of Vpr, when delivered through the cortex, showed neuronal damage only around the site of injection. Interestingly, the number of apoptotic neurons were significantly higher with HIV-1 vectors expressing Vpr than by the SNV vectors. This may be due to the differences in the proteins expressed by these viral vectors. These results suggest that Vpr induces apoptosis in CNS cells in vitro and in vivo. To our knowledge, this is the first study to investigate the apoptosis-inducing capabilities of HIV-1Vpr in vivo in neonatal mice. We propose that this, in expensive animal model, may be of value to design-targeted neuroprotective therapeutics.
- Published
- 2007
- Full Text
- View/download PDF
31. Pentoxifylline suppresses transduction by HIV-1-based vectors.
- Author
-
Smith JA, Nunnari G, Preuss M, Pomerantz RJ, and Daniel R
- Subjects
- Ataxia Telangiectasia Mutated Proteins, Cell Cycle Proteins antagonists & inhibitors, Cell Cycle Proteins genetics, Cell Line, Humans, Protein Serine-Threonine Kinases antagonists & inhibitors, Protein Serine-Threonine Kinases genetics, Virus Integration drug effects, Virus Replication drug effects, Antiviral Agents pharmacology, Genetic Vectors drug effects, HIV-1 drug effects, Pentoxifylline pharmacology, Transduction, Genetic
- Abstract
Pentoxifylline, a caffeine-related compound, was shown to suppress human immunodeficiency virus type 1 (HIV-1) replication. This effect is thought to be mediated by inhibition of tumor necrosis factor-alpha (TNFalpha)-mediated long-terminal repeat (LTR)-driven expression. We now demonstrate that pentoxifylline efficiently inhibits transduction by HIV-1-based vectors. This latter effect is independent of LTR-driven expression, and correlates with a reduced efficiency of the completion of the integration process in infected cells. Finally, the effect of pentoxifylline is dramatically reduced in cells expressing a dominant negative ATR protein, and in primary human cells that exhibit low level of ATR activity, suggesting that the effect of pentoxifylline on HIV-1 transduction and replication is at least partly mediated by suppression of the ATR kinase., ((c) 2007 S. Karger AG, Basel.)
- Published
- 2007
- Full Text
- View/download PDF
32. Mutation of the Rev-binding loop in the human immunodeficiency virus 1 leader causes a replication defect characterized by altered RNA trafficking and packaging.
- Author
-
Greatorex JS, Palmer EA, Pomerantz RJ, Dangerfield JA, and Lever AML
- Subjects
- Animals, COS Cells, Chlorocebus aethiops, Gene Expression Regulation, Viral, Protein Binding, RNA, Viral genetics, Virus Assembly genetics, Virus Replication genetics, Genes, rev genetics, HIV-1 genetics, Mutation genetics, RNA Transport, RNA, Viral metabolism, Virus Assembly physiology, Virus Replication physiology
- Abstract
An internal RNA loop, located within the packaging signal of human immunodeficiency virus 1, that resembles the Rev-responsive element (RRE) closely was identified previously. Subsequent in vitro studies confirmed that the loop, termed loop A, could bind Rev protein specifically. Its proximity to the major splice donor has suggested a role for Rev-loop A interaction supplementary to or preceding that of the Rev-RRE interaction. To investigate this further in a replication-competent provirus, loop A was mutated to decrease its affinity for Rev. Impairing the Rev-loop A interaction led to reduced nuclear export of viral genomic RNA. RNA packaging decreased by approximately 30%. Viral protein production and export of virus particles appeared normal; however, the virus was severely replication-deficient. The loop A sequence, which is 98% conserved amongst viral isolates, is implicated in several cis-acting functions critical to virus viability.
- Published
- 2006
- Full Text
- View/download PDF
33. Rabies virus glycoprotein as a carrier for anthrax protective antigen.
- Author
-
Smith ME, Koser M, Xiao S, Siler C, McGettigan JP, Calkins C, Pomerantz RJ, Dietzschold B, and Schnell MJ
- Subjects
- Animals, Anthrax blood, Anthrax immunology, Antibodies, Bacterial blood, Antibodies, Viral blood, Antibody Specificity, Antigens, Bacterial immunology, Antigens, Viral immunology, Bacterial Toxins immunology, Bioterrorism prevention & control, Genetic Vectors immunology, Glycoproteins immunology, Immunization Schedule, Injections, Intramuscular, Lymphocyte Count, Lymphocytes cytology, Lymphocytes immunology, Mice, Rabies Vaccines immunology, Recombination, Genetic, Th2 Cells immunology, Vaccines, Synthetic administration & dosage, Viral Envelope Proteins immunology, Anthrax prevention & control, Anthrax Vaccines administration & dosage, Antigens, Bacterial genetics, Antigens, Viral genetics, Bacillus anthracis immunology, Bacterial Toxins genetics, Genetic Vectors genetics, Glycoproteins genetics, Rabies Vaccines genetics, Vaccination, Viral Envelope Proteins genetics
- Abstract
Live viral vectors expressing foreign antigens have shown great promise as vaccines against viral diseases. However, safety concerns remain a major problem regarding the use of even highly attenuated viral vectors. Using the rabies virus (RV) envelope protein as a carrier molecule, we show here that inactivated RV particles can be utilized to present Bacillus anthracis protective antigen (PA) domain-4 in the viral membrane. In addition to the RV glycoprotein (G) transmembrane and cytoplasmic domains, a portion of the RV G ectodomain was required to express the chimeric RV G anthrax PA on the cell surface. The novel antigen was also efficiently incorporated into RV virions. Mice immunized with the inactivated recombinant RV virions exhibited seroconversion against both RV G and anthrax PA, and a second inoculation greatly increased these responses. These data demonstrate that a viral envelope protein can carry a bacterial protein and that a viral carrier can display whole polypeptides compared to the limited epitope presentation of previous viral systems.
- Published
- 2006
- Full Text
- View/download PDF
34. Inhibition of endogenous reverse transcription of human and nonhuman primate lentiviruses: potential for development of lentivirucides.
- Author
-
Argyris EG, Dornadula G, Nunnari G, Acheampong E, Zhang C, Mehlman K, Pomerantz RJ, and Zhang H
- Subjects
- Cells, Cultured, Dideoxynucleotides, Disease Transmission, Infectious prevention & control, HIV-1 genetics, Humans, Lentivirus Infections prevention & control, Lentivirus Infections transmission, Simian Immunodeficiency Virus genetics, T-Lymphocytes, Zidovudine pharmacology, Antiviral Agents pharmacology, HIV-1 drug effects, Nevirapine pharmacology, Reverse Transcriptase Inhibitors pharmacology, Simian Immunodeficiency Virus drug effects, Thymine Nucleotides pharmacology, Transcription, Genetic drug effects, Zidovudine analogs & derivatives
- Abstract
In the current study, we extended our previous works on natural endogenous reverse transcription (NERT) and further examined its potential as a virucide molecular target in sexual transmission of primate lentiviruses. HIV-1 and SIV virions were pretreated with select nucleoside (NRTIs) and nonnucleoside RT inhibitors (NNRTIs), either alone or in combination with NERT-stimulating substances. The effects of these antiretrovirals on virion inactivation were analyzed in human T cell lines and primary cell cultures. Pretreatment of HIV-1 virions with physiologic NERT-stimulants and 3'-azido-3'-deoxythymidine 5'-triphosphate (AZT-TP) or nevirapine potently inactivated cell-free HIV-1 virions and resulted in strong inhibition of the viral infectivity. Pretreatment of chimeric SHIV-RT virions with NERT-stimulating cocktail and select antiretrovirals also resulted in virion inactivation and inhibition of viral infectivity in T cell lines. Our findings demonstrate the potential clinical utility of approaches based on inhibiting NERT in sexual transmission of HIV-1, through the development of effective anti-HIV-1 microbicides, such as NRTIs and NNRTIs.
- Published
- 2006
- Full Text
- View/download PDF
35. siRNA targeting vaccinia virus double-stranded RNA binding protein [E3L] exerts potent antiviral effects.
- Author
-
Dave RS, McGettigan JP, Qureshi T, Schnell MJ, Nunnari G, and Pomerantz RJ
- Subjects
- Base Sequence, Cell Line, Down-Regulation, Genes, Viral, HeLa Cells, Humans, Immunity, Innate drug effects, Immunity, Innate genetics, Interferon Type I pharmacology, Interferon-beta biosynthesis, Models, Biological, Recombinant Proteins, Transcription, Genetic, Transfection, Vaccinia virus immunology, Vaccinia virus physiology, Variola virus drug effects, Variola virus genetics, Variola virus immunology, Virus Replication drug effects, Antiviral Agents pharmacology, RNA, Small Interfering genetics, RNA, Small Interfering pharmacology, RNA-Binding Proteins antagonists & inhibitors, RNA-Binding Proteins genetics, Vaccinia virus drug effects, Vaccinia virus genetics, Viral Proteins antagonists & inhibitors, Viral Proteins genetics
- Abstract
The Vaccinia virus gene, E3L, encodes a double-stranded RNA [dsRNA]-binding protein. We hypothesized that, owing to the critical nature of dsRNA in triggering host innate antiviral responses, E3L-specific small-interfering RNAs [siRNAs] should be effective antiviral agents against pox viruses, for which Vaccinia virus is an appropriate surrogate. In this study, we have utilized two human cell types, namely, HeLa and 293T, one which responds to interferon [IFN]-beta and the other produces and responds to IFN-beta, respectively. The antiviral effects were equally robust in HeLa and 293T cells. However, in the case of 293T cells, several distinct features were observed, when IFN-beta is activated in these cells. Vaccinia virus replication was inhibited by 97% and 98% as compared to control infection in HeLa and 293T cells transfected with E3L-specific siRNAs, respectively. These studies demonstrate the utility of E3L-specific siRNAs as potent antiviral agents for small pox and related pox viruses.
- Published
- 2006
- Full Text
- View/download PDF
36. IL-7 as a potential therapy for HIV-1-infected individuals.
- Author
-
Nunnari G and Pomerantz RJ
- Subjects
- Animals, Antiretroviral Therapy, Highly Active methods, Antiretroviral Therapy, Highly Active trends, Drug Therapy, Combination, HIV Infections immunology, Humans, Interleukin-7 pharmacology, Viral Load methods, Viral Load trends, HIV Infections drug therapy, Interleukin-7 therapeutic use
- Abstract
Highly active antiretroviral therapy (HAART), although effective in ameliorating the quality of life of HIV-1-infected individuals and their survival, has not been able to eradicate HIV-1. In fact, when HAART is interrupted, HIV-1 plasma viral load rebounds from viral reservoirs such as resting CD4+ T lymphocytes, monocytes and macrophages, remaining a major obstacle in attempting HIV eradication. Different therapeutic strategies have been attempted, such as structured treatment interruption (STI), immunotherapy (interleukin [IL]-2 and anti-CD3 antibodies [e.g., OKT3]), to try to stimulate HIV-1 out of latency along with antiretroviral intensification therapy. IL-7, a pleiotropic cytokine, bears diverse immune properties and plays a major role in T cell homeostasis. Moreover, IL-7 has recently been investigated as a possible immune adjuvant as well as a viral strain-specific inducer of HIV-1 replication. In fact, IL-7 was shown not only to be more effective than IL-2 in stimulating HIV-1 replication from resting CD4+ T lymphocytes ex vivo, but also to selectively induce a specific HIV-1 viral strain as compared with IL-2, suggesting the potential need for different viral inducers if complete eradication is to be achieved. In this present review, different immunological and virological properties of IL-7 are discussed, along with the possibility of its use as part of a combined antiretroviral-immune rationally based HIV-1 eradication approach.
- Published
- 2005
- Full Text
- View/download PDF
37. Attenuation of HIV-1 infection by other microbial agents.
- Author
-
Kannangara S, DeSimone JA, and Pomerantz RJ
- Subjects
- Disease Progression, HIV Infections virology, Humans, Tuberculosis complications, Virus Replication, Flaviviridae Infections complications, HIV Infections complications, HIV-1 physiology, HTLV-I Infections complications, HTLV-II Infections complications, Measles complications, Scrub Typhus complications
- Abstract
Although potentiation of human immunodeficiency virus (HIV) type 1 (HIV-1) infection has been known to occur in coinfection with a variety of pathogens and types of vaccination, there are emerging data on specific infectious agents that may attenuate HIV-1 infection. New literature suggests that certain pathogens are capable of inhibiting HIV-1 replication. These include GB virus C, measles virus, Orientia tsutsugamushi, and human T lymphotropic virus types 1 and 2. In addition, there are conflicting data on the effects of Mycobacterium tuberculosis on the replication of HIV-1, with some suggesting that this organism may inhibit HIV-1 replication. Also remaining controversial are the possible protective effects of HIV type 2 against HIV-1 infection. In this review, we summarize and critically discuss the body of emerging literature concerning infections that may have the ability to attenuate HIV-1 infection.
- Published
- 2005
- Full Text
- View/download PDF
38. Seminal reservoirs during an HIV type 1 eradication trial.
- Author
-
Nunnari G, Leto D, Sullivan J, Xu Y, Mehlman KE, Kulkosky J, and Pomerantz RJ
- Subjects
- Amino Acid Sequence, Antiretroviral Therapy, Highly Active, DNA, Viral, Didanosine therapeutic use, HIV-1 genetics, Humans, Hydroxyurea therapeutic use, Immunosuppressive Agents therapeutic use, Interleukin-2 therapeutic use, Male, Molecular Sequence Data, Muromonab-CD3 therapeutic use, Nucleic Acid Synthesis Inhibitors therapeutic use, Phylogeny, Proviruses genetics, RNA, Viral, Sequence Alignment, Treatment Outcome, Viremia, Withholding Treatment, Anti-HIV Agents therapeutic use, HIV Envelope Protein gp120 genetics, HIV Infections drug therapy, HIV Infections virology, HIV-1 isolation & purification, Peptide Fragments genetics, Semen virology
- Abstract
Despite dramatic reduction of the levels of human immunodeficiency virus type I (HIV-1) virions in blood and seminal plasma of infected patients, highly active antiretroviral therapy (HAART) does not eradicate HIV-1. Three patients, with less than 50 copies/ml of plasma viral RNA, were enrolled in this eradication protocol. Didanosine (DDI) and hydroxyurea (HU) were added to their baseline HAART and after a month of therapy, low dose OKT3, followed by a 2-week course of interleukin 2 (IL-2), was administrated. All antiretroviral therapy was then interrupted and the three patients developed viral rebound in the peripheral blood. The V3 loop region of the HIV-1 gp120 from cell-free viral RNA and proviral DNA in blood and seminal compartments was sequenced in one patient. The two major viral isolates in semen cells were macrophage- tropic (R5) and dual-tropic (R5X4), and these isolates were also present in the PBMCs. Six months after the viral rebound, we demonstrated a shift toward dual tropism in semen cell-associated HIV-1 proviral DNA, with the first appearance of a T-lymphotropic (X4) provirus solely in this compartment. The virus responsible for the blood plasma viral rebound was never found in the semen microenvironment. This study suggests viral compartmentalization of the semen microenvironment after an intensification and stimulatory HIV-1 eradication protocol, with evidence of viral evolution.
- Published
- 2005
- Full Text
- View/download PDF
39. Exogenous IL-7 induces Fas-mediated human neuronal apoptosis: potential effects during human immunodeficiency virus type 1 infection.
- Author
-
Nunnari G, Xu Y, Acheampong EA, Fang J, Daniel R, Zhang C, Zhang H, Mukhtar M, and Pomerantz RJ
- Subjects
- Astrocytes cytology, Astrocytes immunology, Astrocytes virology, Cells, Cultured, DNA-Binding Proteins metabolism, Gene Expression immunology, Genomics, HIV Envelope Protein gp120 metabolism, Humans, Milk Proteins metabolism, Neurons cytology, Neurons immunology, Oligonucleotide Array Sequence Analysis, RNA, Messenger analysis, Receptors, Interleukin-7 genetics, STAT5 Transcription Factor, Trans-Activators metabolism, Virus Replication immunology, Apoptosis immunology, HIV Infections immunology, HIV-1, Interleukin-7 genetics, Neurons virology, fas Receptor metabolism
- Abstract
The use of exogenous cytokines is part of translational immune-antiretroviral approaches to induce immune reconstitution and possibly eliminate the persistence of human immunodeficiency virus type 1 (HIV-1) in virally suppressed infected individuals on highly active antiretroviral therapy (HAART). Recently, our laboratories demonstrated that interleukin-7 (IL-7) has significant efficiency in stimulating HIV-1 replication from proviral latency in CD4+ T lymphocytes of infected patients. The authors now investigated the possible role of IL-7 in HIV-1-associated dementia (HAD). The authors demonstrated that the IL-7 receptor is expressed on both human neurons (i.e., differentiated NT2 cells) and human astrocytes, with relatively higher mRNA levels in neurons. The translational protein levels of IL-7 receptor alpha were not proportional to those of the mRNA levels in these central nervous system (CNS)-based cell types. Exogenous IL-7 was observed to only slightly down-regulate IL-7 receptor alpha expression on both neurons and astrocytes, as assayed by Western blotting. Instead of promoting survival, surprisingly, exogenous IL-7 induced neuronal apoptosis, as detected by TUNEL assays. Furthermore, IL-7 augmented neuronal apoptosis induced by HIV-1 gp120. Human apoptosis genomic microarray analyses of IL-7-treated human neurons showed up-regulated expression of proapoptotic genes: protein kinases, caspase-10, FAST kinase, tumor necrosis factor (TNF) receptor, and BCL2-antagonist of cell death. These data suggest that IL-7 leads to neuronal apoptosis by a molecular mechanism(s) that occurs via Fas-mediated activation-induced cell death. These studies may therefore not only be key in evaluating the potential use of IL-7 in vivo as a therapeutic modality, but also suggest that IL-7, which is increased endogenously in HIV-1-infected individuals late in disease, may be involved in the neuronal apoptosis demonstrated during HAD.
- Published
- 2005
- Full Text
- View/download PDF
40. HIV type 1 cervicovaginal reservoirs in the era of HAART.
- Author
-
Nunnari G, Sullivan J, Xu Y, Nyirjesy P, Kulkosky J, Cavert W, Frank I, and Pomerantz RJ
- Subjects
- Antiretroviral Therapy, Highly Active, Female, HIV-1 drug effects, Humans, RNA, Viral analysis, Cervix Uteri virology, HIV-1 isolation & purification, Vagina virology
- Abstract
Highly active antiretroviral therapy (HAART) does not lead to viral eradication, due to HIV-1 residual disease. We investigated whether the cervicovaginal tract serves as a viral reservoir. Seven out of eight cervicovaginal fluids were positive for cell-free HIV-1, by supersensitive reverse transcriptase-polymerase chain reactions (RT-PCR), with a detection limit of 1 copy/ml. No viral outgrowth, intracellular proviral DNA, or viral RNA was detected from cervicovaginal lavage and ecto- and endocervical cells. The cervicovaginal tract of patients on HAART is likely not a major solid tissue reservoir for HIV-1. Nonetheless, the presence of even low cell-free HIV-1 RNA in cervicovaginal secretions continues to suggest the importance of practicing protected sex, even in the era of HAART.
- Published
- 2005
- Full Text
- View/download PDF
41. Molecular interactions of human immunodeficiency virus type 1 with primary human oral keratinocytes.
- Author
-
Acheampong EA, Parveen Z, Muthoga LW, Wasmuth-Peroud V, Kalayeh M, Bashir A, Diecidue R, Mukhtar M, and Pomerantz RJ
- Subjects
- Acquired Immunodeficiency Syndrome prevention & control, Acquired Immunodeficiency Syndrome transmission, Apoptosis, HIV-1 isolation & purification, Humans, Keratinocytes physiology, Mouth Mucosa physiology, Oligonucleotide Array Sequence Analysis, HIV-1 physiology, Keratinocytes virology, Mouth Mucosa virology
- Abstract
Infection of the oral mucosa of human immunodeficiency virus type 1 (HIV-1)-infected individuals remains an under-evaluated and somewhat enigmatic process. Nonetheless, it is of profound importance in the ongoing AIDS pandemic, based on its potential as a site of person-to-person transmission of the virus as well as a location of HIV-1 pathogenesis and potential reservoir of disease in the setting of virally suppressive highly active antiretroviral therapy. We utilized molecular and virological techniques to analyze HIV-1 infection of primary human mucosal cells and also evaluated the proapoptotic potential of selected HIV-1 proteins in primary isolated human oral keratinocytes. Primary isolated human oral keratinocytes were plated on 0.4 microM polyethylenetetraphthalate cell culture inserts to form an in vitro oral mucosal layer. The strength of this layer in forming a barrier was determined by measuring trans-epithelial electrical current passage across the monolayer. The oral keratinocyte monolayers had trans-epithelial electrical resistance of approximately 176 to 208 omega. For viral infectivity assays, the macrophage-tropic (R5) HIV-1 strains, YU-2 and ADA, and T-cell-line-tropic (X4), NL4-3 virions, incubated with or without deoxynucleoside triphosphates (dNTPs) and/or the polyamines spermine and spermidine, were used to infect oral keratinocytes. Of importance, polyamines and dNTPs have been shown to enhance natural endogenous reverse transcription (NERT), a step essential for early lentiviral infection, and are abundantly present in human semen. The infectivities of HIV-1 strains YU-2, ADA, and NL4-3 for these primary keratinocytes were dramatically increased by the addition of physiological concentrations of dNTPs, spermine, and spermidine. Binding and viral internalization assay studies showed no differences in these oral mucosal cells, with or without NERT-altering agents. It was also observed that the recombinant, cell-free HIV-1 proteins Nef, Tat, and gp120 (R5) induced apoptosis in primary oral keratinocytes compared with the results seen with nontreated cells or cells treated with glutathione S-transferase protein as a control under similar conditions. Microarray analyses suggested that HIV-1 gp120 and Tat induce apoptosis in primary human oral keratinocytes via the Fas/FasL apoptotic pathway, whereas induction of apoptosis by Nef occurs through both Fas/FasL and mitochondrial apoptotic pathways. Thus, these findings suggest molecular mechanisms by which semen in particular, as well as other bodily fluids such as cervicovaginal secretions, could increase oral transmission of HIV-1 via increasing infectivity in confluent and low-replicating oral keratinocytes. As well, the induction of apoptosis in human oral keratinocytes with relevant HIV-1-specific proteins suggests another potential complementary mechanism by which the oral mucosa barrier may be disrupted during HIV-1 infection in vivo.
- Published
- 2005
- Full Text
- View/download PDF
42. The RNA helicase DDX1 is involved in restricted HIV-1 Rev function in human astrocytes.
- Author
-
Fang J, Acheampong E, Dave R, Wang F, Mukhtar M, and Pomerantz RJ
- Subjects
- Astrocytes metabolism, Astrocytes virology, Cell Nucleus metabolism, Cells, Cultured, Cytoplasm metabolism, DEAD-box RNA Helicases, Humans, RNA Helicases metabolism, Virus Replication, rev Gene Products, Human Immunodeficiency Virus, Gene Products, rev physiology, HIV-1 physiology, RNA Helicases physiology
- Abstract
Productive infection by human immunodeficiency virus type I (HIV-1) in the central nervous system (CNS) involves mainly macrophages and microglial cells. A frequency of less than 10% of human astrocytes is estimated to be infectable with HIV-1. Nonetheless, this relatively low percentage of infected astrocytes, but associated with a large total number of astrocytic cells in the CNS, makes human astrocytes a critical part in the analyses of potential HIV-1 reservoirs in vivo. Investigations in astrocytic cell lines and primary human fetal astrocytes revealed that limited HIV-1 replication in these cells resulted from low-level viral entry, transcription, viral protein processing, and virion maturation. Of note, a low ratio of unspliced versus spliced HIV-1-specific RNA was also investigated, as Rev appeared to act aberrantly in astrocytes, via loss of nuclear and/or nucleolar localization and diminished Rev-mediated function. Host cellular machinery enabling Rev function has become critical for elucidation of diminished Rev activity, especially for those factors leading to RNA metabolism. We have recently identified a DEAD-box protein, DDX1, as a Rev cellular co-factor and now have explored its potential importance in astrocytes. Cells were infected with HIV-1 pseudotyped with envelope glycoproteins of amphotropic murine leukemia viruses (MLV). Semi-quantitative reverse transcriptase-polymerase chain reactions (RT-PCR) for unspliced, singly-spliced, and multiply-spliced RNA clearly showed a lower ratio of unspliced/singly-spliced over multiply-spliced HIV-1-specific RNA in human astrocytes as compared to Rev-permissive, non-glial control cells. As well, the cellular localization of Rev in astrocytes was cytoplasmically dominant as compared to that of Rev-permissive, non-glial controls. This endogenous level of DDX1 expression in astrocytes was demonstrated directly to lead to a shift of Rev sub-cellular distribution dominance from nuclear and/or nucleolar to cytoplasmic, as input of exogenous DDX1 significantly altered both Rev sub-cellular localization from cytoplasmic to nuclear predominance and concomitantly increased HIV-1 viral production in these human astrocytes. We conclude that altered DDX1 expression in human astrocytes is, at least in part, responsible for the unfavorable cellular microenvironment for Rev function in these CNS-based cells. Thus, these data suggest a molecular mechanism(s) for restricted replication in astrocytes as a potential low-level site of residual HIV-1 in vivo.
- Published
- 2005
- Full Text
- View/download PDF
43. Current status of gene therapy strategies to treat HIV/AIDS.
- Author
-
Strayer DS, Akkina R, Bunnell BA, Dropulic B, Planelles V, Pomerantz RJ, Rossi JJ, and Zaia JA
- Subjects
- Animals, Genetic Vectors genetics, Humans, Mice, Models, Animal, Transgenes, Acquired Immunodeficiency Syndrome therapy, Genetic Therapy methods, HIV Infections therapy, HIV-1 genetics, HIV-1 physiology
- Abstract
Progress in developing effective gene transfer approaches to treat HIV-1 infection has been steady. Many different transgenes have been reported to inhibit HIV-1 in vitro. However, effective translation of such results to clinical practice, or even to animal models of AIDS, has been challenging. Among the reasons for this failure are uncertainty as to the most effective cell population(s) to target, the diffuseness of these target cells in the body, and ineffective or insufficiently durable gene delivery. Better understanding of the HIV-1 replicative cycle, host factors involved in HIV-1 infection, vector biology and application, transgene technology, animal models, and clinical study design have all contributed vastly to planning current and future strategies for application of gene therapeutic approaches to the treatment of AIDS. This review focuses on the newest developments in these areas and provides a strong basis for renewed optimism that gene therapy will have an important role to play in treating people infected with HIV-1.
- Published
- 2005
- Full Text
- View/download PDF
44. Inhibition of HIV-1 replication by caffeine and caffeine-related methylxanthines.
- Author
-
Nunnari G, Argyris E, Fang J, Mehlman KE, Pomerantz RJ, and Daniel R
- Subjects
- Ataxia Telangiectasia Mutated Proteins, Cell Cycle Proteins metabolism, Cell Line, Cells, Cultured, DNA-Binding Proteins metabolism, HIV-1 classification, HIV-1 genetics, HIV-1 physiology, Humans, Phosphorylation drug effects, Protein Serine-Threonine Kinases metabolism, Theophylline pharmacology, Time Factors, Tumor Suppressor Proteins metabolism, Caffeine pharmacology, HIV-1 drug effects, Protein Kinase Inhibitors pharmacology, Virus Replication drug effects, Xanthines pharmacology
- Abstract
Human immunodeficiency virus type I (HIV-1) DNA integration is an essential step of viral replication. We have suggested recently that this stage of HIV-1 life-cycle triggers a cellular DNA damage response and requires cellular DNA repair proteins for its completion. These include DNA-PK (DNA-dependent protein kinase), ATR (ataxia telangiectasia and Rad3-related), and, at least in some circumstances, ATM (ataxia telangiectasia mutated). Host cell proteins may constitute an attractive target for anti-HIV-1 therapeutics, since development of drug resistance against compounds targeting these cellular cofactor proteins is unlikely. In this study, we show that an inhibitor of ATR and ATM kinases, caffeine, can suppress replication of infectious HIV-1 strains, and provide evidence that caffeine exerts its inhibitory effect at the integration step of the HIV-1 life-cycle. We also demonstrate that caffeine-related methylxanthines including the clinically used compound, theophylline, act at the same step of the HIV-1 life-cycle as caffeine and efficiently inhibit HIV-1 replication in primary human cells. These data reveal the feasibility of therapeutic approaches targeting host cell proteins and further support the hypothesis that ATR and ATM proteins are involved in retroviral DNA integration.
- Published
- 2005
- Full Text
- View/download PDF
45. ATM: HIV-1's Achilles heel?
- Author
-
Daniel R and Pomerantz RJ
- Subjects
- Ataxia Telangiectasia Mutated Proteins, Cell Cycle Proteins antagonists & inhibitors, Cell Cycle Proteins metabolism, Cell Death drug effects, Cell Death physiology, Cells, Cultured, DNA Repair drug effects, DNA Repair physiology, DNA-Binding Proteins antagonists & inhibitors, DNA-Binding Proteins metabolism, HIV Infections drug therapy, HIV Protease Inhibitors pharmacology, HIV-1 drug effects, Humans, Morpholines pharmacology, Protein Serine-Threonine Kinases antagonists & inhibitors, Protein Serine-Threonine Kinases metabolism, Pyrones pharmacology, Tumor Suppressor Proteins antagonists & inhibitors, Tumor Suppressor Proteins metabolism, Virus Replication drug effects, HIV Infections virology, HIV-1 physiology, Virus Replication physiology
- Published
- 2005
- Full Text
- View/download PDF
46. Down-modulation of the CXCR4 co-receptor by intracellular expression of a single chain variable fragment (SFv) inhibits HIV-1 entry into primary human brain microvascular endothelial cells and post-mitotic neurons.
- Author
-
Mukhtar M, Acheampong E, Khan MA, Bouhamdan M, and Pomerantz RJ
- Subjects
- Antigens metabolism, Brain cytology, Brain virology, Cells, Cultured, Down-Regulation, Embryo, Mammalian, Enzyme-Linked Immunosorbent Assay methods, Fluorescent Antibody Technique methods, HIV Core Protein p24 metabolism, HIV Infections, HIV-1 immunology, Humans, Intracellular Fluid metabolism, Intracellular Fluid virology, Microtubule-Associated Proteins metabolism, Mitosis physiology, Receptors, CXCR4 immunology, Time Factors, Transduction, Genetic methods, Virus Replication, von Willebrand Factor immunology, Endothelial Cells virology, HIV-1 physiology, Immunoglobulin Variable Region metabolism, Neurons virology, Receptors, CXCR4 metabolism
- Abstract
Our laboratories previously demonstrated that expression of a single chain variable antibody fragment (SFv), anti-CXCR4 SFv, in human lymphoid cells suppresses surface display of the chemokine co-receptor CXCR4 and inhibits infectious entry of human immunodeficiency virus type I (HIV-1). We now sought to extend these results to two types of central nervous system (CNS) cells, primary isolated human brain microvascular endothelial cells (MVECs), and post-mitotic differentiated human neurons, both of which normally express significant levels of CXCR4. The anti-CXCR4 SFv expression construct was delivered using an HIV-1-based vector, and control cells received LacZ-expressing viral particles. Upon intracellular expression of the anti-CXCR4 SFv, immunostaining revealed a marked reduction in surface display of CXCR4 on both cell types. Consequently, post-mitotic neurons expressing the anti-CXCR4 SFv were significantly protected from HIV-1 infection, as measured by HIV-1 p24 antigen production, and partial protection was observed in human brain MVECs. The ability to selectively down-modulate the surface expression of CXCR4 in CNS cells may allow for the development of clinical molecular therapy strategies against HIV-1-related neurodegenerative disorders and neuroinvasion.
- Published
- 2005
- Full Text
- View/download PDF
47. Human Immunodeficiency virus type 1 Nef potently induces apoptosis in primary human brain microvascular endothelial cells via the activation of caspases.
- Author
-
Acheampong EA, Parveen Z, Muthoga LW, Kalayeh M, Mukhtar M, and Pomerantz RJ
- Subjects
- Blotting, Western, Brain blood supply, Brain virology, Cells, Cultured, Enzyme Activation, Gene Deletion, Gene Products, nef genetics, Genetic Vectors, Humans, Oligonucleotide Array Sequence Analysis, RNA, Messenger analysis, nef Gene Products, Human Immunodeficiency Virus, Apoptosis, Caspases metabolism, Endothelial Cells physiology, Endothelial Cells virology, Gene Products, nef metabolism, HIV-1 pathogenicity
- Abstract
The lentiviral protein Nef plays a major role in the pathogenesis of human immunodeficiency virus type I (HIV-1) infection. Although the exact mechanisms of its actions are not fully understood, Nef has been shown to be essential for the maintenance of high-titer viral replication and disease pathogenesis in in vivo models of simian immunodeficiency virus infection of monkeys. Nef has also been suggested to play a pivotal role in the depletion of T cells by promoting apoptosis in bystander cells. In this context, we investigated the ability of extracellular and endogenously expressed HIV-1 Nef to induce apoptosis in primary human brain microvascular endothelial cells (MVECs). Human brain MVECs were exposed to baculovirus-expressed HIV-1 Nef protein, an HIV-1-based vector expressing Nef, spleen necrosis virus (SNV)-Nef virus (i.e., SNV vector expressing HIV-1 Nef as a transgene), and the HIV-1 strain ADA and its Nef deletion mutant, ADADeltaNef. We observed that ADA Nef, the HIV-1 vector expressing Nef, and SNV-Nef were able to induce apoptosis in a dose-dependent manner. The mutant virus with a deletion in Nef was able to induce apoptosis in MVECs to modest levels, but the effects were not as pronounced as with the wild-type HIV-1 strain, ADA, the HIV-1-based vector expressing Nef, or SNV-Nef viruses. We also demonstrated that relatively high concentrations of exogenous HIV-1 Nef protein were able to induce apoptosis in MVECs. Gene microarray analyses showed increases in the expression of several specific proapoptotic genes. Western blot analyses revealed that the various caspases involved with Nef-induced apoptosis are processed into cleavage products, which occur only during programmed cell death. The results of this study demonstrate that Nef likely contributes to the neuroinvasion and neuropathogenesis of HIV-1, through its effects on select cellular processes, including various apoptotic cascades.
- Published
- 2005
- Full Text
- View/download PDF
48. Ethanol potentiates HIV-1 gp120-induced apoptosis in human neurons via both the death receptor and NMDA receptor pathways.
- Author
-
Chen W, Tang Z, Fortina P, Patel P, Addya S, Surrey S, Acheampong EA, Mukhtar M, and Pomerantz RJ
- Subjects
- AIDS Dementia Complex etiology, AIDS Dementia Complex pathology, Cells, Cultured, Gene Expression Profiling, Humans, Receptors, N-Methyl-D-Aspartate agonists, TNF Receptor-Associated Factor 5 genetics, Apoptosis drug effects, Ethanol toxicity, HIV Envelope Protein gp120 physiology, HIV-1 pathogenicity, Neurons drug effects, Neurons pathology, Receptors, N-Methyl-D-Aspartate drug effects, Receptors, N-Methyl-D-Aspartate physiology, Receptors, Tumor Necrosis Factor drug effects, Receptors, Tumor Necrosis Factor physiology
- Abstract
Neuronal loss is a hallmark of AIDS dementia syndromes. Human immunodeficiency virus type I (HIV-1)-specific proteins may induce neuronal apoptosis, but the signal transduction of HIV-1 gp120-induced, direct neuronal apoptosis remains unclear. Ethanol (EtOH) is considered to be an environmental co-factor in AIDS development. However, whether EtOH abuse in patients with AIDS increases neuronal dysfunction is still uncertain. Using pure, differentiated, and post-mitotic NT2.N-derived human neurons, we investigated the mechanisms of HIV-1 and/or EtOH-related direct neuronal injury and the molecular interactions between HIV-1-specific proteins and EtOH. It was demonstrated that NT2.N neurons were susceptible to HIV-1 Bal (R5-tropic strain) gp120-induced direct cell death. Of importance, EtOH induced cell death in human neurons in a clinically-relevant dose range and EtOH strongly potentiated HIV-1 gp120-induced neuronal injury at low and moderate concentrations. Furthermore, this potentiation of neurotoxicity could be blocked by N-methyl-D-aspartate (NMDA) receptor subunit 2B (NR2B) antagonists. We analyzed human genomic profiles in these human neurons, using Affymetrix genomics technology, to elucidate the apoptotic pathways involved in HIV-1- and EtOH-related neurodegeneration. Our findings indicated significant over-expression of selected apoptosis functional genes. Significant up-regulation of TRAF5 gene expression may play an essential role in triggering potentiation by EtOH of HIV-1 gp120-induced neuronal apoptosis at early stages of interaction. These studies suggested that two primary apoptotic pathways, death receptor (extrinsic) and NMDA receptor (intrinsic)-related programmed cell-death pathways, are both involved in the potentiation by EtOH of HIV-1 gp120-induced direct human neuronal death. Thus, these data suggest rationally-designed, molecular targets for potential anti-HIV-1 neuroprotection.
- Published
- 2005
- Full Text
- View/download PDF
49. Spleen necrosis virus-based vector delivery of anti-HIV-1 genes potently protects human hematopoietic cells from HIV-1 infection.
- Author
-
Marusich EI, Parveen Z, Strayer D, Mukhtar M, Dornburg RC, and Pomerantz RJ
- Subjects
- Gene Transfer Techniques, Genetic Vectors, HIV Infections, Humans, Leukocytes, Mononuclear cytology, Leukocytes, Mononuclear virology, Transduction, Genetic, HIV-1 physiology, Hematopoietic Stem Cells virology, Spleen Focus-Forming Viruses genetics, Virus Replication
- Abstract
In this study, we report on the efficacy of using a spleen necrosis virus (SNV)-based vector delivery system to block human immunodeficiency virus type I (HIV-1) replication in human hematopoietic cells. These efforts were directed towards the development of human immune system cell resistance to HIV-1 infection, based on the strategy of "intracellular immunization" via generation of a series of anti-HIV-1 therapeutic constructs carrying scFvs, single-chain variable fragments, against HIV-1 integrase and reverse transcriptase in combination with the trans-dominant mutant of HIV-1 Rev, RevM10. The efficiency of the anti-HIV-1 constructs were tested in viral challenge assays with different doses of HIV-1 NL4-3, Bal, 89.6 and R7-GFP strains. These experiments demonstrated the reduction of HIV-1 replication by these retroviral vector constructs in a range of 4- to 10-fold in CD4+ T-lymphocytes, human peripheral blood mononuclear cells (PBMCs), and primary human macrophages. We observed selective efficiency of SNV-based therapeutics in H9, C8166 and Jurkat T-lymphocytic cell lines, demonstrating the most efficient inhibition of HIV-1 replication in Jurkat T-cells. Thus, these data are the first demonstration of the ability of SNV-based retroviral vectors with select transgenes, which may have certain molecular advantages over other retroviral vector systems, to combat HIV-1 replication in human hematopoietic cells and support the potential for using SNV-expressed constructs in anti-HIV-1 molecular therapeutics.
- Published
- 2005
- Full Text
- View/download PDF
50. Caffeine inhibits human immunodeficiency virus type 1 transduction of nondividing cells.
- Author
-
Daniel R, Marusich E, Argyris E, Zhao RY, Skalka AM, and Pomerantz RJ
- Subjects
- Cell Cycle Proteins metabolism, Cell Line, Genetic Vectors, HIV-1 genetics, HIV-1 physiology, Humans, Caffeine pharmacology, HIV-1 drug effects, Transduction, Genetic, Virus Integration drug effects
- Abstract
Caffeine is an efficient inhibitor of DNA repair and DNA damage-activated checkpoints. We have shown recently that caffeine inhibits retroviral transduction of dividing cells, most likely by blocking postintegration repair. This effect may be mediated at least in part by a cellular target of caffeine, the ataxia telangiectasia-mutated and Rad3-related (ATR) kinase. In this study, we present evidence that caffeine also inhibits efficient transduction of nondividing cells. We observed reduced transduction in caffeine-treated growth-arrested cells as well as caffeine-treated terminally differentiated human neurons and macrophages. Furthermore, this deficiency was observed with a human immunodeficiency virus type 1 (HIV-1) vector lacking Vpr, indicating that the effect is independent of the presence of this viral protein in the infecting virion. Finally, we show that HIV-1 transduction of nocodazole-arrested cells is reduced in cells that express an ATR dominant-negative protein (kinase-dead ATR [ATRkd]) and that the residual transduction of ATRkd-expressing cells is relatively resistant to caffeine. Taken together, these data suggest that the effect(s) of caffeine on HIV-1 transduction is mediated at least partly by the inhibition of the ATR pathway but is not dependent on the caffeine-mediated inhibition of cell cycle checkpoints.
- Published
- 2005
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.